Pharmacokinetics of caspofungin and voriconazole in critically ill patients during extracorporeal membrane oxygenation

Journal of Antimicrobial Chemotherapy

Volumn 63, Issue 4, 2009, Pages 767-770

  Spriet, Isabel ^a   Annaert, Pieter ^b   Meersseman, Philippe ^a   Hermans, Greet ^a   Meersseman, Wouter ^a   Verbesselt, Rene ^a   Willems, Ludo ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b DEPARTMENT OF PHARMACEUTICAL AND PHARMACOLOGICAL SCIENCES   (Belgium)

Author keywords

Antifungals; Plasma levels; Therapeutic drug monitoring

Indexed keywords

AMIKACIN; CASPOFUNGIN; FLUCONAZOLE; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; VORICONAZOLE;

ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTICLE; ARTIFICIAL VENTILATION; ASPERGILLOSIS; CANDIDA ALBICANS; CANDIDIASIS; CASE REPORT; CRITICAL ILLNESS; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ELIMINATION; DRUG MONITORING; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EXTRACORPOREAL OXYGENATION; HALF LIFE TIME; HUMAN; LOADING DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; PANCREATITIS; PLASMA CONCENTRATION-TIME CURVE; SEPTIC SHOCK; TOXIC MEGACOLON;

ADOLESCENT; ADULT; ANTIFUNGAL AGENTS; CRITICAL ILLNESS; ECHINOCANDINS; EXTRACORPOREAL MEMBRANE OXYGENATION; HUMANS; MALE; PLASMA; PYRIMIDINES; TRIAZOLES;

EID: 62549138761     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp026     Document Type: Article

References (10)

1. Bartlett R, Roloff D, Custer J et al. Extracorporeal life support. The University of Michigan Experience. JAMA 2000; 283: 904-8.
2. Buck ML. Pharmacokinetic changes during extracorporeal membrane oxygenation. Implications for drug therapy of neonates. Clin Pharmacokinet 2003; 42: 403-17.
3. Mehta NM, Halwick DR, Dodson BL et al. Potential drug sequestration during extracorporeal membrane oxygenation: Results from an ex vivo experiment. Intensive Care Med 2007; 33: 1018-24.
4. Schwartz M, Kline W, Matuszewski B. Determination of a cyclic hexapeptide (L-743872), a novel pneumocandin antifungal agent in human plasma and urine by high-performance liquid chromatography with fluorescence detection. Anal Chim Acta 1997; 352: 299-307.
5. Khoschsorur G, Fruehwirth F, Zelzer S. Isocratic highperformance liquid chromatographic method with ultraviolet detection for simultaneous determination of levels of voriconazole and itraconazole and its hydroxyl metabolite in human serum. Antimicrob Agents Chemother 2005; 49: 3569-71.
6. Stone JA, Holland SD, Wickersham PJ et al. Single- and multiple-dose pharmacokinetics of caspofungin in healthy men. Antimicrob Agents Chemother 2002; 46: 739-45.
7. Nguyen TH, Hoppe-Tichy T, Geiss HK et al. Factors influencing caspofungin plasma concentrations in patients of a surgical intensive care unit. J Antimicrob Chem 2007; 60: 100-6.
8. Ruiz S, Papy E, Da Silva D et al. Potential voriconazole and caspofungin sequestration during extracorporeal membrane oxygenation. Intensive Care Med 2009; 35: 183-4.
9. Wishart DS, Knox C, Guo AC et al. DrugBank: A knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res 2008; 36: D901-6.
10. Brüggemann RJ, Donnelly JP, Aarnoutse RE et al. Therapeutic drug monitoring of voriconazole. Ther Drug Monit 2008; 30: 403-11.